4 completed, 1 not yet recruiting, 1 terminated, 1 unknown. 7 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 7 | Completed 4, Not yet recruiting 1, Terminated 1, Unknown 1 |
Follow Oppositional Defiant Disorder: new trials by email Literature Review of Oppositional Defiant Disorder trials Research Report on Oppositional Defiant Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD Clonidine extended release oral suspension, Placebo - Attention-deficit/Hyperactivity Disorder, Oppositional Defiant Disorder in Children | Phase 4 | Not yet recruiting | Las Vegas Medical Research, LLC DBA Vector Clinical Trials | 162 | 2025-07-01 | 2025-07-01 |
| Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Methylphenidate, Risperidone - Attention Deficit/Hyperactivity Disorder, Oppositional Defiant Disorder | Phase 4 | Terminated | Sheba Medical Center | 5 | 2017-02-01 | 2020-03-18 |
| Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Parent Management Training, Placebo, Intuniv - Intermittent Explosive Disorder, Childhood Aggression | Phase 4 | Completed | New York State Psychiatric Institute | 11 | 2011-07-01 | 2018-06-13 |
| Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study) Valproate, Risperidone, Placebo - Attention Deficit Disorder With Hyperactivity | Phase 4 | Unknown | Joseph Blader | 270 | 2008-11-01 | 2012-07-16 |
| Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Atomoxetine, Placebo - Attention Deficit Hyperactivity Disorder, Oppositional Defiant Disorder | Phase 4 | Completed | Eli Lilly and Company | 181 | 2006-11-01 | 2010-02-26 |
| Metabolic Effects of Antipsychotics in Children risperidone, olanzapine, aripiprazole - Aggression, Attention Deficit-Hyperactivity | Phase 4 | Completed | Washington University School of Medicine | 144 | 2006-04-01 | 2018-06-15 |
| Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Divalproex Sodium, Methylphenidate, Dextroamphetamine - Attention Deficit Disorder With Hyperactivity, Conduct Disorder | Phase 4 | Completed | Stony Brook University | 40 | 2004-01-01 | 2013-10-31 |
Attention Deficit Disorder with Hyperactivity (6) · Aggression (4) · Conduct Disorder (3) · Behavior (1) · Bipolar Disorder (1) · Child Development Disorders, Pervasive (1) · Disruptive, Impulse Control, and Conduct Disorders (1)
Attention Deficit and Disruptive Behavior Disorders (7) · Mental Disorders (7) · Neurodevelopmental Disorders (7) · Aberrant Motor Behavior in Dementia (4) · Behavioral Symptoms (4) · Social Behavior (4) · Behavior (3) · Bipolar and Related Disorders (1) · Mood Disorders (1)
Methylphenidate (3) · Risperidone (3) · Dextroamphetamine (2) · Valproic Acid (2) · Aripiprazole (1) · Atomoxetine Hydrochloride (1) · Family Therapy (1) · Guanfacine (1) · Olanzapine (1) · Sugars (1)
Eli Lilly and Company (1) · Joseph Blader (1) · Las Vegas Medical Research, LLC DBA Vector Clinical Trials (1) · New York State Psychiatric Institute (1) · Sheba Medical Center (1) · Stony Brook University (1) · Washington University School of Medicine (1)
United States (4) · Germany (1) · Israel (1)
Joseph C. Blader, PhD, MSc (2) · Ann Childress, MD (1) · Doron Gothelf, professor (1) · Ginger Nicol, MD (1) · John W. Newcomer, MD (1) · Stephen J Donovan, MD (1)
PMID 24290461, PMID 26745211, PMID 19884222, PMID 25019647, PMID 29898210, PMID 32007604
K23MH064975 (1), M01RR010710 (1), R01MH072912 (1)